83 FR 29128 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 121 (June 22, 2018)

Page Range		29128-29129
FR Document		2018-13418

Federal Register, Volume 83 Issue 121 (Friday, June 22, 2018)

[Federal Register Volume 83, Number 121 (Friday, June 22, 2018)]
[Notices]
[Pages 29128-29129]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-13418]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Receptor Profiling and Predictive Toxicology (8937).
    Date: July 19, 2018.
    Time: 10:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).

[[Page 29129]]

    Contact Person: Lyle Furr, Scientific Review Officer, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Synthetic Peptides and Other Drugs of Abuse--Purity 
Determination, Stability Testing, & Quantitative Analysis (8945).
    Date: August 7, 2018.
    Time: 10:00 a.m. to 12:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Lyle Furr, Scientific Review Officer, Office of 
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 
Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
9550, (301) 827-5702, lf33c.nih.gov.

(Catalogue of Federal Domestic Assistance Program No.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)


    Dated: June 19, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-13418 Filed 6-21-18; 8:45 am]
 BILLING CODE 4140-01-P

29128 Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices

Disclosure Agreement will be required trimeric pre-fusion HIV-1 Env. Nature. Place: National Institutes of Health, 5635
to receive copies of unpublished patent 2014 Oct 23; 514(7523):455–61. [PMID: Fishers Lane, Bethesda, MD 20892 (Virtual
applications. 25296255]. Meeting).
Intellectual Property: HHS Reference Contact Person: Anne E. Schaffner, Ph.D.,
SUPPLEMENTARY INFORMATION: Chief, Scientific Review Branch, Division of
Technology description follows. Number E–178–2014 includes U.S. Extramural Research, National Eye Institute,
Provisional Patent Application No. 62/ 5635 Fishers Lane, Suite 1300, MSC 9300,
Recombinant HIV-1 Envelope Protein 046,059 filed September 4, 2014; U.S. Bethesda, MD 20892–9300, (301) 451–2020,
for Vaccine Use Provisional Patent Application No. 62/ aes@nei.nih.gov.
Description of Technology 136,480 filed March 21, 2015; PCT Name of Committee: National Eye Institute
Application No. PCT/US2015/048729 Special Emphasis Panel; NEI Research
In pursuit of an effective vaccine to filed September 4, 2015; U.S. Patent Project Grant Applications (R01).
end the global HIV-1/AIDS pandemic, Application No. 15/508,885 filed March Date: July 25, 2018.
researchers at the Vaccine Research 3, 2017; and EPO Patent Application Time: 12:00 p.m. to 2:00 p.m.
Center (‘‘VRC’’) continue to study the No. 15766697.5 filed March 29, 2017. Agenda: To review and evaluate grant
structure of HIV-1. Recently, these applications.
Licensing Contact: Dr. Barry
researchers have determined the three- Place: National Institutes of Health 5635
Buchbinder, 240–627–3674; Fishers Lane, Bethesda, MD 20892
dimensional structure of the HIV-1 barry.buchbinder@nih.gov. (Telephone Conference Call).
Envelope trimeric ectodomain (‘‘Env’’), Collaborative Research Opportunity: Contact Person: Brian Hoshaw, Ph.D.,
comprised of three gp120 and three The National Institute of Allergy and Scientific Review Officer National Eye
gp41 subunits, in its prefusion, mature, Infectious Diseases is seeking statements Institute National Institutes of Health,
closed conformation. of capability or interest from parties Division of Extramural Research 5635 Fishers
The researchers hypothesize that interested in collaborative research to Lane, Suite 1300, Rockville, MD 20892, 301–
immunization with the prefusion, further develop, evaluate, or 451–2020, hoshawb@mail.nih.gov.
closed HIV-1 Env protein will elicit a commercialize HIV-1 immunogens for (Catalogue of Federal Domestic Assistance
neutralizing immune response. The VRC treating or preventing HIV-1 infection. Program Nos. 93.867, Vision Research,
National Institutes of Health, HHS)
researchers engineered a portion of the For collaboration opportunities, please
HIV-1 Env trimer to stabilize it in this contact Dr. Barry Buchbinder, 240–627– Dated: June 19, 2018.
closed conformation for use as an 3674; barry.buchbinder@nih.gov. Natasha M. Copeland,
immunogen. Dated: June 14, 2018. Program Analyst, Office of Federal Advisory
This technology is available for Committee Policy.
Suzanne M. Frisbie,
licensing for commercial development Deputy Director, Technology Transfer and
[FR Doc. 2018–13413 Filed 6–21–18; 8:45 am]
in accordance with 35 U.S.C. 209 and 37 Intellectual Property Office, National Institute BILLING CODE 4140–01–P
CFR part 404, as well as for further of Allergy and Infectious Diseases.
development and evaluation under a [FR Doc. 2018–13416 Filed 6–21–18; 8:45 am]
research collaboration. DEPARTMENT OF HEALTH AND
BILLING CODE 4140–01–P
HUMAN SERVICES
Potential Commercial Applications
• Vaccine for prevention of HIV-1 National Institutes of Health
DEPARTMENT OF HEALTH AND
infection. HUMAN SERVICES National Institute on Drug Abuse;
• Therapeutic vaccine for treatment
Notice of Closed Meetings
of HIV-1 infection. National Institutes of Health
Pursuant to section 10(d) of the
Competitive Advantages National Eye Institute; Notice of Closed Federal Advisory Committee Act, as
• Currently, no licensed HIV-1 Meetings amended, notice is hereby given of the
vaccine exists. following meetings.
Pursuant to section 10(d) of the
The meetings will be closed to the
Development Stage Federal Advisory Committee Act, as
public in accordance with the
• In vitro studies characterizing the amended, notice is hereby given of the
provisions set forth in sections
immunogen and its interaction with HIV following meetings.
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
The meetings will be closed to the
antibodies. as amended. The contract proposals and
• In vivo results including public in accordance with the
the discussions could disclose
immunogenicity in rabbits and guinea provisions set forth in sections
confidential trade secrets or commercial
pigs, neutralizing activity of resulting 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
property such as patentable material,
serum. as amended. The grant applications and
and personal information concerning
Inventors: Peter D. Kwong (NIAID), the discussions could disclose
individuals associated with the contract
Ivelin S. Georgiev (NIAID), Michael confidential trade secrets or commercial
proposals, the disclosure of which
Gordon Joyce (NIAID), Marie L. Pancera property such as patentable material,
would constitute a clearly unwarranted
(NIAID), Tongqing Zhou (NIAID), and personal information concerning
invasion of personal privacy.
Priyamvada Acharya (NIAID), Jason J. individuals associated with the grant
applications, the disclosure of which Name of Committee: National Institute on
Gorman (NIAID), Yongping Yang Drug Abuse Special Emphasis Panel;
(NIAID), Aliaksandr A. Druz (NIAID), would constitute a clearly unwarranted
Receptor Profiling and Predictive Toxicology
Guillaume Stewart-Jones (NIAID), Rita invasion of personal privacy. (8937).
daltland on DSKBBV9HB2PROD with NOTICES

Chen (NIAID), Gwo-Yu Chuang (NIAID), Name of Committee: National Eye Institute Date: July 19, 2018.
Ulrich Baxa (NIAID), John R. Mascola Special Emphasis Panel; NEI Cooperative Time: 10:00 a.m. to 12:30 p.m.
(NIAID), Rebecca M. Lynch (NIAID), Agreement (UG1) and Clinical Trial Planning Agenda: To review and evaluate contract
Grant (R34) Applications. proposals.
Baoshan Zhang (NIAID), Cheng Cheng Date: July 13, 2018. Place: National Institutes of Health,
(NIAID). Time: 1:00 p.m. to 4:00 p.m. Neuroscience Center, 6001 Executive
Publications: Pancera M., et al. Agenda: To review and evaluate Boulevard, Rockville, MD 20852 (Telephone
Structure and immune recognition of cooperative agreement applications. Conference Call).

VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1

Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 29129

Contact Person: Lyle Furr, Scientific Place: Embassy Suites DC Convention Name of Committee: Center for Scientific
Review Officer, Office of Extramural Affairs, Center, 900 10th Street NW, Washington, DC Review Special Emphasis Panel; Member
National Institute on Drug Abuse, NIH, 20001. Conflict: Motivated Behavior.
DHHS, Room 4227, MSC 9550, 6001 Contact Person: Sussan Paydar, Ph.D., Date: July 11–12, 2018.
Executive Boulevard, Bethesda, MD 20892– Scientific Review Officer, Center for Time: 8:00 a.m. to 5:00 p.m.
9550, (301) 827–5702, lf33c.nih.gov. Scientific Review, National Institutes of Agenda: To review and evaluate grant
Name of Committee: National Institute on Health, 6701 Rockledge Drive, RM 5222, applications.
Drug Abuse Special Emphasis Panel; Bethesda, MD 20817, (301) 827–4994, Place: National Institutes of Health, 6701
Synthetic Peptides and Other Drugs of sussan.paydar@nih.gov. Rockledge Drive, Bethesda, MD 20892
Abuse—Purity Determination, Stability This notice is being published less than 15 (Virtual Meeting).
Testing, & Quantitative Analysis (8945). days prior to the meeting due to the timing Contact Person: Michael Selmanoff, Ph.D.,
Date: August 7, 2018. limitations imposed by the review and Scientific Review Officer, Center for
Time: 10:00 a.m. to 12:30 p.m. funding cycle.
Scientific Review, National Institutes of
Agenda: To review and evaluate contract (Catalogue of Federal Domestic Assistance Health, 6701 Rockledge Drive, Room 5164,
proposals. Program Nos. 93.306, Comparative Medicine; MSC 7844, Bethesda, MD 20892, 301–435–
Place: National Institutes of Health, 93.333, Clinical Research, 93.306, 93.333, 1119, selmanom@csr.nih.gov.
Neuroscience Center, 6001 Executive 93.337, 93.393–93.396, 93.837–93.844,
Boulevard, Rockville, MD 20852 (Telephone 93.846–93.878, 93.892, 93.893, National Name of Committee: AIDS and Related
Conference Call). Institutes of Health, HHS) Research Integrated Review Group; HIV/
Contact Person: Lyle Furr, Scientific AIDS Vaccines Study Section.
Dated: June 18, 2018. Date: July 13, 2018.
Review Officer, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH, Sylvia L. Neal, Time: 8:00 a.m. to 6:00 p.m.
DHHS, Room 4227, MSC 9550, 6001 Program Analyst, Office of Federal Advisory Agenda: To review and evaluate grant
Executive Boulevard, Bethesda, MD 20892– Committee Policy. applications.
9550, (301) 827–5702, lf33c.nih.gov. [FR Doc. 2018–13389 Filed 6–21–18; 8:45 am] Place: Embassy Suites at the Chevy Chase
(Catalogue of Federal Domestic Assistance BILLING CODE 4140–01–P Pavilion, 4300 Military Road NW,
Program No.: 93.279, Drug Abuse and Washington, DC 20015.
Addiction Research Programs, National Contact Person: Barna Dey, Ph.D.,
Institutes of Health, HHS) DEPARTMENT OF HEALTH AND Scientific Review Officer, Center for
HUMAN SERVICES Scientific Review, National Institutes of
Dated: June 19, 2018. Health, 6701 Rockledge Drive, Room 3184,
Natasha M. Copeland, National Institutes of Health Bethesda, MD 20892, 301–435–0000, bdey@
Program Analyst, Office of Federal Advisory mail.nih.gov.
Committee Policy. Center for Scientific Review; Notice of Name of Committee: Center for Scientific
[FR Doc. 2018–13418 Filed 6–21–18; 8:45 am] Closed Meetings Review Special Emphasis Panel; Member
BILLING CODE 4140–01–P Conflict: Molecular Mechanisms of
Pursuant to section 10(d) of the Alzheimer’s Disease, Synaptic Function, and
Federal Advisory Committee Act, as Neurodevelopment.
amended, notice is hereby given of the Date: July 17, 2018.
DEPARTMENT OF HEALTH AND
following meetings. Time: 10:00 a.m. to 4:00 p.m.
HUMAN SERVICES The meetings will be closed to the Agenda: To review and evaluate grant
National Institutes of Health public in accordance with the applications.
provisions set forth in sections Place: National Institutes of Health, 6701
Center for Scientific Review; Notice of 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Rockledge Drive, Bethesda, MD 20892
Closed Meeting as amended. The grant applications and (Virtual Meeting).
the discussions could disclose Contact Person: Carol Hamelink, Ph.D.,
Pursuant to section 10(d) of the confidential trade secrets or commercial Scientific Review Officer, Center for
Federal Advisory Committee Act, as property such as patentable material, Scientific Review, National Institutes of
amended, notice is hereby given of the and personal information concerning Health, 6701 Rockledge Drive, Room 4192,
following meeting. individuals associated with the grant MSC 7850, Bethesda, MD 20892, (301) 213–
The meeting will be closed to the applications, the disclosure of which 9887, hamelinc@csr.nih.gov.
public in accordance with the would constitute a clearly unwarranted Name of Committee: Center for Scientific
provisions set forth in sections invasion of personal privacy. Review Special Emphasis Panel; PAR–17–
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 340: Collaborative Program Grant for
Name of Committee: Center for Scientific Multidisciplinary Teams (RM1).
as amended. The grant applications and Review Special Emphasis Panel; Date: July 17, 2018.
the discussions could disclose Neurodevelopmental Disorders. Time: 11:00 a.m. to 5:00 p.m.
confidential trade secrets or commercial Date: June 27, 2018. Agenda: To review and evaluate grant
property such as patentable material, Time: 12:00 p.m. to 3:00 p.m.
applications.
and personal information concerning Agenda: To review and evaluate grant
Place: National Institutes of Health, 6701
individuals associated with the grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892.
applications, the disclosure of which Rockledge Drive, Bethesda, MD 20892 Contact Person: Thomas Beres, Ph.D.,
would constitute a clearly unwarranted (Telephone Conference Call). Scientific Review Officer, Center for
invasion of personal privacy. Contact Person: Pat Manos, Ph.D., Scientific Review, National Institutes of
Scientific Review Officer, Center for Health, 6701 Rockledge Drive, Room 5148,
Name of Committee: Center for Scientific
MSC 7840, Bethesda, MD 20892, 301–435–
daltland on DSKBBV9HB2PROD with NOTICES

Review Special Emphasis Panel; Scientific Review, National Institutes of
Fellowships: Biophysical, Physiological, Health, 6701 Rockledge Drive, Room 5200, 1175, berestm@mail.nih.gov.
Pharmacological and Bioengineering MSC 7846, Bethesda, MD 20892, 301–408– (Catalogue of Federal Domestic Assistance
Neuroscience. 9866, manospa@csr.nih.gov. Program Nos. 93.306, Comparative Medicine;
Date: June 28, 2018. This notice is being published less than 15 93.333, Clinical Research, 93.306, 93.333,
Time: 8:00 a.m. to 8:00 p.m. days prior to the meeting due to the timing 93.337, 93.393–93.396, 93.837–93.844,
Agenda: To review and evaluate grant limitations imposed by the review and 93.846–93.878, 93.892, 93.893, National
applications. funding cycle. Institutes of Health, HHS)

VerDate Sep<11>2014 17:16 Jun 21, 2018 Jkt 244001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\22JNN1.SGM 22JNN1

Document Created: 2018-11-06 09:50:28
Document Modified: 2018-11-06 09:50:28

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		July 19, 2018.
FR Citation		83 FR 29128

83 FR 29128 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 121 (June 22, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health